---
document_datetime: 2025-10-14 14:51:21
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/menveo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: menveo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7246329
conversion_datetime: 2025-12-29 22:48:13.833222
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Menveo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 11/09/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000269053                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of the section 4.8 of the SmPC in order to provide a single adverse drug reaction (ADR) table for all age groups with reviewed frequencies of ADRs based on the pooled data from studies V59P20, V59P7, V59P8, and V59P10 concerning children 2 to 10 years of age, studies V59P13, V59P18, V59P17, V59P6, and V59P11 concerning individuals 11 to 65 years of age, and studies V59_71 and V59_78 conducted to compare Menveo formulations, and post- marketing data; the Package Leaflet is updated accordingly. The MAH is taking the opportunity to align the SmPC with latest QRD template and SmPC guideline, to update the list of local representatives in the Package Leaflet, and to introduce editorial   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000272754 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | starting material/intermediate - Accepted                                                                                                                                                                                                                                                                                                                                                                |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000264612 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted                                                                                                                                                                                                                                                                                              | 16/05/2025 | N/A |
| Variation type II / EMA/VR/0000245250 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.c The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - Accepted | 15/05/2025 | N/A |